Long-term outcomes of TIPS assessed by MRI features in patients with portal hypertension and hepatocellular carcinoma: A retrospective study.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
In hepatocellular carcinoma (HCC) complicated by portal hypertension (PHT), transjugular intrahepatic portosystemic shunt (TIPS) relieves portal pressure but its long-term net benefit remains debated. Multiparametric magnetic resonance imaging (MRI) may refine candidate selection by capturing tumor biology and hepatic hemodynamics. We conducted a single-center retrospective cohort (January 2020-December 2022) including 150 HCC patients with PHT who underwent baseline MRI (TIPS, n = 80; control, n = 70). Demographics, liver function, tumor burden, and MRI metrics - tumor apparent diffusion coefficient (ADC), liver stiffness by magnetic resonance elastography, and spleen volume - were collected. The primary endpoint was 36-month overall survival (OS); secondary endpoints were progression-free survival (PFS), ≥Grade II overt hepatic encephalopathy (OHE), variceal rebleeding, and TIPS stenosis. Survival was compared by Kaplan-Meier analysis; independent predictors were identified using Cox models. A nomogram incorporating TIPS, ADC, liver stiffness, Child-Pugh class, and alpha-fetoprotein was built and validated. At 36 months, the TIPS group showed higher OS than controls (69.0% vs 50.0%; HR 0.56, 95% CI: 0.34-0.92; P = .021) and better PFS (65.0% vs 42.9%; P = .006). Rates of death, disease progression, OHE, and rebleeding were all reduced with TIPS (all P < .05). Higher tumor ADC (≥1.10 × 10-3 mm2/s; HR 0.48, 95% CI: 0.29-0.80) and lower liver stiffness (<5 kPa; HR 0.63, 95% CI: 0.40-0.98) independently predicted improved OS, whereas Child-Pugh C was adverse (HR 1.72, 95% CI: 1.05-2.80). The MRI-clinical nomogram achieved area under the receiver operating characteristic curves (AUCs) of 0.830, 0.820, and 0.798 for predicting 1-, 2-, and 3-year OS, with favorable calibration and decision-curve net benefit. TIPS confers a significant long-term survival advantage in HCC with PHT while reducing major complications. Quantitative MRI metrics (tumor ADC and liver stiffness) refine preprocedural risk stratification, and the combined MRI-clinical nomogram provides practical decision support.